Patents by Inventor Keiko Kakegawa

Keiko Kakegawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic compound
    Patent number: 11958845
    Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 26, 2022
    Date of Patent: April 16, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Hideyuki Sugiyama, Takeshi Yamamoto, Keiko Kakegawa, Jinxing Li, Junsi Wang, Takahito Kasahara, Masato Yoshikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20230183227
    Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I) wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: September 26, 2022
    Publication date: June 15, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro ITO, Hideyuki SUGIYAMA, Takeshi YAMAMOTO, Keiko KAKEGAWA, Jinxing LI, Junsi WANG, Takahito KASAHARA, Masato YOSHIKAWA
  • ANTI-ALS COMPOUNDS
    Publication number: 20230037538
    Abstract: The present invention relates to compounds expected to be useful in the prevention and/or treatment of diseases such as amyotrophic lateral sclerosis, frontotemporal dementia, chronic traumatic encephalopathy, Alzheimer's disease, frontotemporal lobar degeneration, multisystem proteinopathy and the like, a method for preventing or treating such diseases, and the like.
    Type: Application
    Filed: June 23, 2022
    Publication date: February 9, 2023
    Inventors: Dennis Solas, Anatoliy Kitaygorodskyy, Kumar Paulvannan, Vishwanath R. Lingappa, Masato Yoshikawa, Masahiro Ito, Yuta Tanaka, Keiko Kakegawa, Tomohiro Ohashi, Takuto Kojima, Akinori Toita, Osamu Kubo, Fumiaki Kikuchi, Florian Pünner, Junsi Wang
  • Heterocyclic compound
    Patent number: 11459325
    Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: October 4, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuta Tanaka, Tomohiro Ohashi, Zenichi Ikeda, Yuta Tanaka, Florian Pünner, Takeshi Yamamoto, Keiko Kakegawa, Fumiaki Kikuchi, Nao Morishita, Takahito Kasahara, Masaki Seto, Minoru Nakamura, Kazuaki Takami, Masataka Murakami, Masaki Daini, Satoshi Mikami, Minoru Sasaki
  • Heterocyclic compound
    Patent number: 11453661
    Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: September 27, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Hideyuki Sugiyama, Takeshi Yamamoto, Keiko Kakegawa, Jinxing Li, Junsi Wang, Takahito Kasahara, Masato Yoshikawa
  • HETEROCYCLIC COMPOUND
    Publication number: 20220289679
    Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 15, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuta TANAKA, Yuta TANAKA, Keiko KAKEGAWA, Takahito KASAHARA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Tomohiro OHASHI, Zenichi IKEDA, Florian PUENNER, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
  • HETEROCYCLIC COMPOUND
    Publication number: 20220274982
    Abstract: The present invention provides a compound having a glucosylceramide synthase inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of lysosomal storage diseases (e.g., Gaucher's disease, Fabry's disease, GM1-gangliosidosis, GM2 activator deficiency, Tay-Sachs disease, Sandhoffs disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: July 28, 2020
    Publication date: September 1, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuta TANAKA, Yuta TANAKA, Fumiaki KIKUCHI, Takeshi YAMAMOTO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Yasufumi WADA, Keiko KAKEGAWA, Takahito KASAHARA, Tomohiro OHASHI, Junsi WANG, Zenichi IKEDA, Florian PUENNER, Masaki SETO, Satoshi MIKAMI, Minoru SASAKI
  • HETEROCYCLIC COMPOUND
    Publication number: 20220098180
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 31, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro ITO, Takeshi YAMAMOTO, Keiko KAKEGAWA, Hideyuki SUGIYAMA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Osamu KUBO, Akinori TOITA, Takuto KOJIMA, Fumiaki KIKUCHI, Minoru SASAKI, Misaki HOMMA, Yasuhiro IMAEDA, Hironobu MAEZAKI, Shiinobu SASAKI, Ayumu SATO, Hirotaka KAMITANI, Yasutomi ASANO, Hironori KOKUBO, Masato YOSHIKAWA
  • Substituted amines for treating cardiac diseases
    Patent number: 11197858
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: January 27, 2020
    Date of Patent: December 14, 2021
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
  • HETEROCYCLIC COMPOUND
    Publication number: 20210094944
    Abstract: The present invention provides a heterocyclic compound having a HDAC6 inhibitory action, which is useful for the treatment of central nervous system diseases including neurodegenerative diseases, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.
    Type: Application
    Filed: September 24, 2020
    Publication date: April 1, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro ITO, Hideyuki SUGIYAMA, Takeshi YAMAMOTO, Keiko KAKEGAWA, Jinxing LI, Junsi WANG, Takahito KASAHARA, Masato YOSHIKAWA
  • HETEROCYCLIC COMPOUND
    Publication number: 20210087186
    Abstract: The present invention provides a compound having a glucosylceramide lowering action (e.g., promoting glucosylceramide metabolism, inhibition of glucosylceramide synthesis, promoting glucosylceramide catabolism, etc.), which is expected to be useful as an agent for the prophylaxis or treatment of lysosome diseases (e.g., Gaucher's disease), neurodegenerative diseases (e.g., Parkinson's disease, Lewy body dementia, multiple-system atrophy) and the like. The present invention relates to a compound represented by the formula (I) wherein each symbol is as described in the specification, or a salt thereof.
    Type: Application
    Filed: January 30, 2019
    Publication date: March 25, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuta TANAKA, Tomohiro OHASHI, Zenichi IKEDA, Yuta TANAKA, Florian PÜNNER, Takeshi YAMAMOTO, Keiko KAKEGAWA, Fumiaki KIKUCHI, Nao MORISHITA, Takahito KASAHARA, Masaki SETO, Minoru NAKAMURA, Kazuaki TAKAMI, Masataka MURAKAMI, Masaki DAINI, Satoshi MIKAMI, Minoru SASAKI
  • SUBSTITUTED AMINES FOR TREATING CARDIAC DISEASES
    Publication number: 20200230137
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: January 27, 2020
    Publication date: July 23, 2020
    Applicant: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
  • Substituted amines for treating cardiac diseases
    Patent number: 10543212
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: January 28, 2020
    Assignee: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki Matsunaga, Takashi Nakahata, Yuta Tanaka, Hiroki Takahagi, Yasufumi Miyamoto, Rei Okamoto, Takeshi Yoshikawa, Yoshito Terao, Takafumi Yukawa, Keiko Kakegawa, Yoichi Nishikawa, Terufumi Takagi, Masashi Takahashi, Mallareddy Komandla, Lily Kwok, Joanne Miura, Mark Sabat, Nicholas Scorah, Paul Tanis, John Tyhonas, Phong H. Vu, Haixia Wang, Xiaolun Wang, Junya Shirai, Tomohiro Okawa, Zenyu Shiokawa, Akito Shibuya
  • HDAC6 inhibitory heterocyclic compound
    Patent number: 10435399
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: October 8, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masahiro Ito, Hideyuki Sugiyama, Osamu Kubo, Fumiaki Kikuchi, Takeshi Yasui, Keiko Kakegawa, Zenichi Ikeda, Tohru Miyazaki, Yasuyoshi Arikawa, Tomohiro Okawa, Jinichi Yonemori, Akinori Toita, Takuto Kojima, Yasutomi Asano, Ayumu Sato, Hironobu Maezaki, Shinobu Sasaki, Hironori Kokubo, Misaki Homma, Minoru Sasaki, Yasuhiro Imaeda
  • HETEROCYCLIC COMPOUND
    Publication number: 20190135799
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of central nervous system diseases including neurodegenerative disease, and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 30, 2018
    Publication date: May 9, 2019
    Inventors: Masahiro ITO, Hideyuki SUGIYAMA, Osamu KUBO, Fumiaki KIKUCHI, Takeshi YASUI, Keiko KAKEGAWA, Zenichi IKEDA, Tohru MIYAZAKI, Yasuyoshi ARIKAWA, Tomohiro OKAWA, Jinichi YONEMORI, Akinori TOITA, Takuto KOJIMA, Yasutomi ASANO, Ayumu SATO, Hironobu MAEZAKI, Shinobu SASAKI, Hironori KOKUBO, Misaki HOMMA, Minoru SASAKI, Yasuhiro IMAEDA
  • HETEROCYCLIC COMPOUND
    Publication number: 20180280389
    Abstract: The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: March 23, 2018
    Publication date: October 4, 2018
    Applicant: Cardurion Pharmaceuticals, LLC
    Inventors: Nobuyuki MATSUNAGA, Takashi NAKAHATA, Yuta TANAKA, Hiroki TAKAHAGI, Yasufumi MIYAMOTO, Rei OKAMOTO, Takeshi YOSHIKAWA, Yoshito TERAO, Takafumi YUKAWA, Keiko KAKEGAWA, Yoichi NISHIKAWA, Terufumi TAKAGI, Masashi TAKAHASHI, Mallareddy KOMANDLA, Lily KWOK, Joanne MIURA, Mark SABAT, Nicholas SCORAH, Paul TANIS, John TYHONAS, Phong H. VU, Haixia WANG, Xiaolun WANG, Junya SHIRAI, Tomohiro OKAWA, Zenyu SHIOKAWA, Akito SHIBUYA
  • Heterocyclic compound
    Patent number: 10023544
    Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: July 17, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Zenichi Ikeda, Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Yoichi Nishikawa
  • Fused heterocyclic compound
    Patent number: 10017487
    Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. Specifically, the present invention relates to a compound represented by the formula (I) or a salt thereof, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like [in the formula, each symbol is as defined in the specification].
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: July 10, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Keiko Kakegawa, Zenichi Ikeda, Minoru Sasaki, Fumiaki Kikuchi, Yoichi Nishikawa
  • Condensed heterocyclic compound
    Patent number: 9975903
    Abstract: The present invention relates to a condensed heterocyclic compound that has an enteropeptidase inhibitory effect and is useful in the treatment or prevention of obesity, diabetes mellitus, or the like, and a medicament containing the same. Specifically, the present invention relates to a compound represented by the following formula (I) or a salt thereof, and a medicament containing the same [in the formula, each symbol is as defined in the specification].
    Type: Grant
    Filed: December 24, 2015
    Date of Patent: May 22, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Minoru Sasaki, Fumiaki Kikuchi, Zenichi Ikeda, Keiko Kakegawa, Yoichi Nishikawa, Shigekazu Sasaki, Koichiro Fukuda, Kazuaki Takami, Yoshihiro Banno, Masahiro Kamaura
  • Fused heterocyclic compound
    Patent number: 9969705
    Abstract: A fused heterocyclic compound having an enteropeptidase inhibitory action and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided. Specifically, a compound represented by the following formula (I): wherein each symbol is as defined herein, or a salt thereof and use of the compound as a medicament for treatment or prophylaxis of obesity, diabetes mellitus, etc., are provided.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: May 15, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Minoru Sasaki, Keiko Kakegawa, Fumiaki Kikuchi, Zenichi Ikeda, Yoichi Nishikawa